To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers and Autosomal Dominant Polycystic Kidney Disease Subjects

Condition:   Autosomal Dominant Polycystic Kidney Interventions:   Drug: AL01211 or Placebo (Part A);   Drug: AL01211 or Placebo (Part B);   Drug: AL01211 or Placebo (Part C) Sponsors:   AceLink Therapeutics, Inc.;   Novotech (Australia) Pty Limited Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials